Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Keenova Therapeutics plc

Life Sciences · 6 alerts · CIK 1567892

Shares outstanding
39.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Keenova Therapeutics plc filings on SEC EDGAR ↗

5:15 PM ET 10-Q
Financial Results

Keenova Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Narrows

Keenova Therapeutics reported net sales of $549.5 million for the quarter ended September 30, 2026, a significant increase from $416.1 million in the prior year. Despite higher revenue, the company recorded a net loss of $96.1 million for the quarter and $430.1 million for the nine-month period, primarily driven by a $150.6 million loss on divestiture and $207.7 million in non-restructuring impairment charges.

Key figure
Net loss $96.1M
6:37 AM ET 8-K
Financial Results

Keenova Therapeutics Financial Results

Keenova Therapeutics reported Q3 2026 net sales of $550 million, driven by strong performance from core brands Acthar Gel and XIAFLEX. The company raised its full-year guidance for net sales and Adjusted EBITDA based on higher growth expectations for XIAFLEX and continued demand for Acthar Gel.

Term
Q3 2026

“On this day last year, Keenova introduced itself as a new company with a new identity and a bright future. Since that day, we have made significant strategic, commercial, operational, and clinical progress toward fulfilling our goal of becoming a pure-play branded therapeutics company. Our third-quarter 2026 results further demonstrate the consistent progress we are making against that goal.”

Siggi Olafsson, Board Chair and Chief Executive Officer

“In the quarter our core brands, Acthar Gel and XIAFLEX, contributed better-than-expected performance, driven primarily by increased demand and improved operational execution. As a result, we are reiterating our full-year net sales growth outlook for Acthar Gel of 20% to 22% and now expect XIAFLEX net sales to grow 10% to 11% year over year.”

Siggi Olafsson, Board Chair and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.